Biotech rNPV Valuation: Formula, Worked Example and Assumption Checklist

The short answer

Risk-adjusted net present value (rNPV) is a scenario model: discount future cash flows and weight them by the probability of reaching the state in which they occur. It is not a prediction that a drug will work.

The most useful output is a list of assumptions the valuation depends on—not a precise-looking price target. Keep operating value, cash and debt, and equity value separate.

A cash-flow-level formula

For each future period:

Program rNPV = sum of [probability-weighted inflows − probability-weighted outflows] / (1 + discount rate)^time.

The probability attached to a cash flow is the probability of reaching its payment state. A near-term trial bill may be incurred even if approval never happens. Multiplying every cost by the probability of approval can therefore understate costs. Costs already paid are not future outflows.

Also state whether your discount rate captures risks already modeled in the probabilities. Do not add a second arbitrary “failure discount” without explaining what additional risk it represents.

A worked example—entirely hypothetical

These figures are teaching assumptions, not industry benchmarks, a live company valuation or a price target. Suppose all amounts below are already discounted to today:

Assumption	Hypothetical value
Success-contingent commercial cash inflows	$300 million
Probability of receiving those inflows	30%
Remaining development spending assumed to occur regardless of approval	$40 million
Cash outside the program valuation	$100 million
Debt	$20 million

Under this deliberately simplified model:

• Program operating value: 30% × $300m − $40m = $50m.
• Assuming it is the company's only operation and there are no other claims or adjustments, equity value: $50m + $100m − $20m = $130m.
• At a hypothetical 20% success probability, the same arithmetic gives $20m operating value and $100m equity value.
• At 40%, it gives $80m operating value and $160m equity value.

The valuation changes because an assumption changes. Nothing in this example estimates a real program's success probability.

Do not compare unlike values

Market capitalization measures equity. Compare it with an equity-value estimate, not an unadjusted sum of operating program values.

A fuller bridge may need non-operating assets, debt-like claims, corporate overhead, royalties, milestones and dilution. Make clear which items are already inside projected cash flows so they are not counted twice.

Aswath Damodaran's DCF valuation questions discuss matching cash flows with discount rates and moving from firm value to equity value. That framework does not supply a biotech-specific probability of success.

Evidence checklist before using the model

• Development stage and evidence: verify the exact study, population, comparator and results. A registry date is not evidence of efficacy.
• Commercial assumptions: state the indication, competitive alternatives, pricing, uptake, time to market and loss of exclusivity. Missing inputs stay UNKNOWN.
• Costs and rights: identify which party pays development costs and receives sales, royalties or milestones.
• Cash, debt and shares: cite the filing period and security/share basis. Do not combine a historical share count with an unexplained current valuation.
• Probability: identify the dataset, period, indication and transition it measures, or label the input as a scenario. Do not present a generic percentage as a verified forecast for this drug.
• Sensitivity: show which uncertain inputs change the conclusion and what new evidence would update them.

Turn the article into research

Choose a company in the task on this page. The research should separate sourced company facts from your scenario assumptions, identify missing inputs and link to the original evidence. It should not manufacture a valuation when the required inputs are absent.

Use company filings and pipeline records, the cash-runway calculator, and the trial-design checklist as starting points.

Editorial correction, October 1, 2026: the earlier article incorrectly called a cash-and-debt-adjusted value “enterprise value.” It also presented broad success-rate and discount-rate ranges without a cited dataset. Those ranges have been removed; the example above is explicitly hypothetical. Research education only, not investment advice.